Effects of Gesture Plus Verbal Treatment (GVT) in Cantonese Speakers With Aphasia (NCT07455162) | Clinical Trial Compass
RecruitingNot Applicable
Effects of Gesture Plus Verbal Treatment (GVT) in Cantonese Speakers With Aphasia
Hong Kong90 participantsStarted 2025-04-01
Plain-language summary
This research aims to explore the relative efficacy of Verbal-only and GVT on naming difficulty in Cantonese-speaking people with aphasia (PWA).
The primary research question in this study is: "For Cantonese-speaking people with aphasia, what are the relative effects of verbal treatment compared to gesture plus verbal treatment (GVT) on verbal and gesture naming at different levels?"
People with aphasia will be engaged in a repeated measures experimental design. Participants will be engaged in two phases of training. In the first phase, participants will be assigned to receive verbal-only treatment. To minimize and prevent the carry-over effects caused by the first intervention, a one-month washout period will be implemented before the start of the second phase. After a washout period, participants will switch to GVT in the second phase.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with aphasia
* Demonstrate Word finding Difficulty (WFD)
* Able to repeat single words
* Normal (or corrected) vision and hearing
* Aphasia resulting from a unilateral left hemisphere stroke
* Premorbidly fluent in spoken Cantonese
* Without significant cognitive impairments
* Chronic aphasia resulting from a unilateral left hemisphere stroke
Exclusion Criteria:
* A history of other neurological disorders
* With the above moderate to severe or severe motor speech impairment
* With moderate to severe apraxia of speech
* With very mild or very severe aphasia
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in the scores of the Naming Probes
Timeframe: From enrollment to the end of treatment at 4 weeks